Chimeric Therapeutics
Chimeric - Model CHM 2301 (CDH17 CAR NK) -NK Cell Derived Allogeneic Therapies
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen Receptor.
Most popular related searches
natural killer cell
natural killer cell therapy
allogeneic cell therapy
antigen receptor
cell therapy
allogeneic cell

